Similarly, more widespread use of PET and CSF measures of amyloid and tau, and, even more importantly, plasma measures of amyloid, tau, and other markers (e.g., NfL, GFAP) (Angioni et al., 2022) will offer more accurate assessment of AD co-pathology. The gene discussed is MAPT; the disease is Alzheimer disease.